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ABSTRACT 
IDENTIFICATION AND THE CHARACTERIZATION OF 
SMALL MOLECULES WITH POTENTIAL ANTICANCER 
ACTIVITY AGAINST SOLID TUMORS  
 
İrem Durmaz 
MSc. in Molecular Biology and Genetics 
Supervisor: Assoc. Prof. Rengül Atalay 
August 2011, 77 Pages 
 
The ultimate goal of our project was to investigate candiate small molecules 
with a potential anticancer activity and characterize their mode of action.  
Cardiac glycosides are important group of molecules for both their treating 
properties in heart failure and their potential effects in cancer therapy. We 
investigated the cardiac glycosides that are extracted from Digitalis Ferruginea 
which can be frequently found in Turkey. These glycosides are Lanatoside A, 
Lanatoside C and Glucogitorosid. Our results showed that they constitute high 
cytotoxicity effect against liver cancer cell lines. In addition they cause G2/M cell 
cycle arrest and thereby induce apoptosis. 
For the synthetic molecules, we first tested a set of molecules that are 
synthesized as derivatives of kinase inhibitors. There are some commercial drugs 
such as imatinib or erlotinib that are used frequently for cancer treatment. Thus we 
wanted to investigate if these molecules comprise cytotoxic activities. Our data 
revealed that especially one of the molecules out of 16 display high cytotoxicity and 
high kinase inhibitory effect in liver cancer cell lines.  
The final group of molecules we tested was compoused of thiazolidine ring. 
In this group of molecules, only one molecule, the one with alkyne terminal 
precursor, caused cytotoxicity against cancer cell lines. Besides, we have shown that 
it induces SubG1/G1 cell cycle arrest in cancer cell lines. 
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ÖZET 
POTANSİYEL ANTİKANSER ÖZELLİKLERE SAHİP 
OLABİLECEK KÜÇÜK MOLEKÜL İNHİBİTÖRLERİNİN 
TEŞHİS EDİLMESİ VE NİTELENDİRİLMESİ 
 
İrem Durmaz 
Moleküler Biyoloji ve Genetik Yüksek Lisansı 
Tez Yöneticisi: Doç. Dr. Rengül Atalay 
Ağustos 2011, 77 Sayfa 
 
Bizim bu projedeki amacımız, anti kanser özelliğe sahip olabilecek 
molekülleri test edip nitelendirmektir.  
İncelediğimiz ilk grup, yüksük otundan elde edilen kalp glikosidleriydi. Bu 
moleküller, gerek kalp hastalığı tedavisinde, gerekse de kanser tedavisindeki 
potansiyel etkileri sebebiyle oldukça araştırılmakta olan moleküllerdir. Bizim 
araştırmalarımız sonucunda da bu maddelerin karaciğer kanseri hücrelerine 
sitotoksik etkileri olduğunu göstermiş bulunmaktayız. Ayrıca bu moleküller, hücre 
bölünme sürecinde G2/M fazında durmaya sebep vererek apoptos indüklenmesine 
neden oldukları deney sonuçları da gösterilmiştir. 
İkinci grup moleküllerimiz sentetik kinaz inhibitör türevleridir. Günümüzde 
kinaz inhibitörü olan imatinib, erlotanib gibi birçok madde kanser tedavisinde 
kullanılmaktadır. Biz de yaptığımız araştırmalar sonucunda gruptaki 16 molekülden 
özellikle bir molekülün oldukça yüksek citotoksik etki ve kinas inhibisyon gücünün 
varlığını göstermiş olduk.  
Son grup moleküller ise tiyazolidin yapısındaki moleküllerden oluşmaktadır. 
Bu grupta da özellikle bir molekülün öne çıktığını gösterdik. Alkin içeren bu molekül 
oldukça yüksek hücre ölümlerine neden oluyor kanser hücre ortamına verildiğinde. 
Ayrıca bu molekülün de hücre bölünme döngüsünde SubG1/G1 fazında durmaya 
sebep olduğunu deney sonuçlarımızda gösterdik. 
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CHAPTER 1. INTRODUCTION 
 
1.1 Small Molecule Inhibitors 
In most of the biological processes, protein-protein interactions play a very 
significant and fundamental role. Therefore, development and characterization of 
small molecules for therapeutic agents, that have the potential to interfere with 
enzyme activities or ion channel activities, attracts the attention of most scientists. 
The ultimate effect of such small molecules is their inhibitory effect on downstream 
protein-protein interactions in cell signaling cascades (Arkin et al, 2004). The reason 
that small molecules provide a very big potential for targeted anticancer research is 
that on the contrary to most of the genetic tools, small molecule inhibitors are 
reversible most of the time. In addition, they can produce responses inside the cells 
that are graded and finally they can easily cross the cellular membrane and penetrate 
inside the cell (Brisson et al, 2004). Novel targets that are aimed to be disrupted by 
small molecule inhibitors include proteins that are involved in various biological 
pathways such as regulation of gene expression, signal transduction, DNA repair, 
cell growth…etc. In most of the cases small molecules compete for ATP-binding 
with other molecules or directly disrupts protein-protein interaction and thus inhibit 
their function (London, C. 2007) 
 
1.2. Cardiac Glycosides 
Cardiac glycosides are steroid-like compounds and include commonly known 
therapeutics such as digitoxin, digoxin and ouabain (Figure 1.1). Digitalis is the most 
widely cardiac glycoside and consists of two components: digitoxin and digoxin 
(Newman et al, 2008). 
Usage of plant extracts containing cardiac glycosides for medical occasions 
trace back to more than 1500 years ago. In the ancient times, they were used as heart 
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tonics, diuretics or arrow poisons. Latter in time, they were shown to be therapeutic 
for heart diseases and even now medical doctors use them in treatment of congestive 
heart failure. In 1975 it was observed that a patient with congestive heart failure 
recovered after treated with foxglove which is the extract taken from Digitalis 
purpurea L (Huxtable et al, 2001). This extract produced from foxglove contains 
cardenolides that was shown to increase contractility of the cardiac muscles and 
regulate atrial fibrillation by functioning like antiarrythmic compounds (Gheorghiade 
et al, 2006; Hamad et al, 2007). Mechanism underlying for their function as 
therapeutic for heart failure is inhibition of Na
+
,K
+
-ATPase (energy transducing ion 
pump) and thus causing an increase in the intracellular concentration of calcium and 
sodium ions. It also leads to a decrease in the concentration of potassium ions 
(Kaplan JH, 2002; Newman et al, 2008).  
 
Figure 1.1: Structural representation some cardiac glycosides  (Newman et al, 2008)  
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1.2.1 Cardiac glycosides and Cancer 
Back in 1960s, it has been reported that in vitro cardiac glycosides can inhibit 
malignant cell formation thus since then various researches has been establish for 
possible anticancer activity of cardiac glycosides (Shiratori et al, 1967; Winnicka et 
al, 2006). In breast cancer it has been shown that, five years after mastectomy, the 
rate of recurrence was 9.6 times fewer in cardiac glycoside taking patients (Stenkvist 
et al, 1982).  Also in another study it was shown that survival rate was higher in 
patients taking cardiac glycosides (Stenkvist et al, 1999).  Moreover, a more recent 
study revealed that ouabin can induce activation of Src/EGFR which causes 
activation of ERK1/2 and thus increase in p21/Cip1 levels and finally cause growth 
arrest. Digitoxin and digoxin also are shown to have similar properties and 
consequences (Kometiani et al, 2006). Furthermore, in another study it has been 
proposed that Na
+
,K
+
-ATPase translocation to the nucleus is responsible for the 
activation/transactivation of Src/EGFR. Then this activation, as previously reported, 
cause Ras activation and thereby MEK and ERK1/2 activation followed by ROS 
production that will either be followed by apoptosis or autophagy (Figure 1.2) 
(Newman et al, 2008; Xie and Cai, 2003; Schoner and Scheiner-Bobis, 2007). There 
are many other studies suggesting other consequences of cardiac glycoside 
application such as inhibition of activator protein-1 (AP-1), Akt and 
phosphoinositide-3 kinase (PI3K) related protein as well as death-receptor regulated 
apoptotic pathway inhibition (Figure 1.2) (Newman et al, 2008; Schoner and 
Scheiner-Bobie, 2007; Chen et al, 2006). 
Fourty years ago, usage of cardiac glycosides was prohibited due to 
possibility of high toxicity. Nonetheless, recent studies revealed that cardiac 
glycosides such as digitoxin and oleandrin are not toxic to tumor cells derived from 
rodent. On the other hand, they inhibit proliferation of human and monkey derived 
tumor cells when applied in nanomolar concentrations (Erdmann and Schoner, 1973; 
Pathak et al, 2000; Gupta et al 1986).  
Thus these findings bring in mind the possibility of tissue specificity. Further 
studies confirmed that cardiac glycosides in fact have tissue specificity such that they  
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are not toxic towards normal cells but malignant cell population (Sreenivasan et al, 
2003). Moreover, cardiac glycosides were shown to induce tumor cells become more 
sensitive towards irradiation (Verheye-Dua and Bohm, 1998). 
 
1.2.2 Apoptosis and Cardiac glycosides 
Apoptosis, which is the regulatory factor for cell number determination and 
damaged cell elimination, is key factor in many biological processes such as 
embryogenesis, immune system regulation or carcinogenesis. It is also called as 
“programmed cell death” that occurs in multicellular organisms. Biggest difference 
between apoptosis and necrosis is that cell debris does not disrupt the surrounding 
cells. There are some surface proteins that when undergoes apoptotic morphological 
changes induce the surrounding cells to phagocytosed the apoptotic cell (Wyllie 
AH).  
In some in vitro studies it has been shown that non-toxic concentrations of 
cardiac glycosides, including digitalis, apoptosis induction is observed. (Haux et al, 
1999; Daniel et al, 2003) Morphological changes caused by cytotoxicity of cardiac 
steroids are very similar to that of apoptosis. For instance phosphatidylserine 
externalization, DNA fragmentation and disruption of mitochondrial membrane 
potential are common morphological changes (Daniel et al, 2003). It has been 
proposed that apoptosis induction property of cardiac glycosides cannot be just 
through inhibition of Na
+
,K
+
-ATPase (Winnicka et al 2006).  
Calcium ion chelators, calcium channel blockers and antagonists of 
calmodulin have the potential to delay or totally inhibit apoptosis. Therefore, it was 
proposed that deregulation of intracellular calcium ion homeostasis by cardiac 
glycosides through inhibition of Na
+
,K
+
-ATPase may induce apoptosis in healthy 
cells as well as cancer cell lines. And this might explain the potential anti-cancer 
activity of cardiac glycosides (McConkey et al, 2000). Moreover, some research 
groups points out that in prostate cancer cell lines, when given in drugable 
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concentrations, cardiac glycosides causes proliferative arrest and apoptosis induction 
(Johansson et al, 2001; Haux et al, 2001). 
Consequently, the alteration of calcium ion concentration might have the 
potential consequence of apoptotic induction in human cancer cell lines producing a 
new area for therapeutic approach (Winnicka et al 2006). 
In another study it has been shown that malignant cells show more 
susceptibility towards cardiac glycosides than of healthy cells. A possible 
explanation for this might be that activity of Na
+
,K
+
-ATPase is altered in tumor cells 
(Racker et al, 1983; Kasarov et al, 1974). For instance, bufalin, type of a cardiac 
glycoside was shown to induce apoptosis in HL60 and ML1 leukemia cell lines but 
no induction was observed in normal cells. The signal transduction for apoptosis 
induction is suggested to be through Ras-Raf1-MAPK pathway (Kometiani et al, 
2006).  In another study it has been shown that inhibition of the decrease in 
potassium levels prevents activation of caspases and therefore apoptosis cannot be 
induced (Hashimoto et al, 1997).  Furthermore, it was also proposed that in 
androgen-independent prostate cancer, three cardiac glycosides, oleandrin, ouabain 
and digoxin induces apoptosis through cytochrome c release (McConkey et al, 2000; 
Ramiez et al, 2007). In some other studies, cardiac glycosides have been proposed to 
increase Fas and tumor necrosis factor receptor (TNFR1) which thus raises the 
induction of apoptosis in tumor cells but not in healthy cells (Newman et al, 2008; 
Sreenivasan et al, 2006). It was reported by another group that in non-small-cell-lung 
cancer cell lines, cardiac glycosides oleandrin, digoxin and digitoxin induces 
apoptosis via activating death receptor pathway (death receptors 4&5) and thus via 
Apo21/TNF-related apoptosis-inducing ligand (TRAIL) pathway (Frese et al, 2006). 
However, the induction of apoptosis by cardiac glycosides is a controversary issue 
and suggested to be tissue specific since in another study of vascular smooth muscle 
cells, apoptosis was shown to be inhibited by cardiac glycosides (Moss, 1998; 
Winnicka et al 2006).  
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Figure 1.2: Na
+
,K
+
-ATPase Signaling cascade (Wasserstromet al, 2005)  
 
 
1.2.3 Angiogenesis and Cardiac Glycosides 
The growth of new capillary blood vessels is called as angiogenesis. It is a 
vital process for tumor formation and progression and also for metastasis. Cardiac 
glycosides have been suggested to regulate activation of fibroblast-growth factor-2 
(FGF-2) which is an angiogenesis inducing molecule. In addition, in the same study, 
NF-kB, which prevents apoptosis induction and induce drug resistance, was shown to 
be inhibited by cardiac glycosides (Cronauer et al, 1997; Oh et al, 1998; Johnson et 
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al, 2002; Wang et al, 1996; Nakshatri et al, 1997). Regulation of FGF-2 was by 
cardiac glycosides was suggested to be through the inhibition of  Na
+
,K
+
-ATPase 
which thus cause the prevention of export of FGF-2 (Smith et al, 2001). On the other 
hand Na
+
,K
+
-ATPase pump was shown to play critical role in membrane transport 
mechanism of some proteins necessary for the growth of the tumor (Florkiewicz et 
al, 1998). 
 
1.2.4 Digitalis Ferruginea 
Digitalis genus, which is suggested to be the main source of cardiac 
glycosides, is composed of over 20 species. In the literature, there is not much study 
done on the cardiac glycosides derived from Digitalis Ferruginea (also known as 
“rusty foxglove”) but mostly from lanata. Using TLC and PC methodology, the 
cardenolide ingredients of some of the Digitalis species have been analyzed and 
Digitalis Ferruginea is one of these species. Previously, Lanatoside A, Lanatoside C, 
Glucogitorosid, Lugrandoside, Ferruginoside A and Ferruginoside B was isolated 
from digitalis ferruginea (Çalış et al, 1999; Davie et al, 1978; Çalış et al, 1999 
 
1.3 Protein Kinases 
Kinase family of proteins is mostly composed of enzymes with regulatory 
functions in the activation/inhibition of other proteins inside the cell. They function 
by adding phosphate groups to amino acid side chains of other proteins. This 
phosphate addition causes structural change of the protein which will cause the 
change in the activity of the protein. This is a reversible action and can be removed 
by protein phosphatases. Kinases are vital component of the cell and have important 
functions in most intracellular pathways such as growth and cell division, cellular 
metabolism or DNA damage (Becker et al, 2003; Novak C, 2004).  
In structural view, protein kinases have two binding sites. One of them is the 
catalytic subunit to where ATP binds. The other binding site is for the target protein. 
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Depending on where the phosphate transferred by the kinase, protein kinases are 
divided into sub groups such as Serine/Threonine kinases, and Tyrosine kinases 
(Hanks et al, 1988).  Even though Tyrosine kinases are less in number when 
compared to Serine/Threonine kinases, they have more critical roles in key 
regulatory cascades. Receptor tyrosine kinases (RTKs) and non-receptor Tyrosine 
kinases (NRTKs) are two subgroups of Tyrosine kinases. RTKs contain extracellular 
ligand-binding domains and intracellular kinase domains and EGFR is an example 
for this group. NRTKs involved in intracellular pathways are cytoplasmic protein 
kinases such as SRC, ABL…etc. Some kinases have dual properties meaning that 
they can add a phosphate group to both Serine-Threonine and Tyrosine hydroxyl side 
chains. Mitogen-activated protein kinase kinases (MKKs) are example of dual-
functional kinases (Arena S et al, 2005).  
 
1.3.1 Deregulation of kinase family of proteins in cancer 
Phosphorylation is the basis of the regulatory circuit of the cell which 
mediates the proper functioning of the proteins acting in cell proliferation, gene 
expression, cellular differentiation, cellular metabolism, protein turnover and cell 
death such as apoptosis (Figure 1.3). In case of abnormalities in phosphorylation of 
proteins mostly tumorigenesis occurrence is observed (Tsuboi et al, 2004, Venture et 
al, 2006).   
In most of the cancer cells, activation of protein kinases and receptor kinases 
is found to be altered (Table 1.1). For instance mitogen activated protein kinase 
(MAPK), phosphotidylinositol-3-kinase (PI3K), AKT, and the epidermal growth 
factor receptor (EGFR) are found to be hyper-activated in cancer cells. Kinases can 
have both oncogenic or tumor suppressive effects in cancer. However, most of the 
time tumor suppressive kinases are found to be serine/threonine or dual-functional 
kinases whereas most proto-oncogene kinases are found to be tyrosine kinases. For 
example, SRC and ABL which are NRTKs, function as proto-oncogene. 
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 On the other hand, death-associated protein kinase-1 (DAPK1), which is a 
serine/threonine kinase, is shown to be tumor suppressive which is down regulated in 
several cancer types including breast and renal carcinoma (Kissil JL et al, 1997, Tend 
DH et al, 1997). Therefore, in several studies protein kinases are therapeutically 
targeted with small molecules or antibodies which has potential to inhibit the 
interaction between the kinase and its substrate or these inhibitors in some cases 
target and inhibit ATP binding site of kinases (Novak C, 2004).   
 
 
 
 
 
 
 
Figure 1.3: Circuit of the cell: Proteins with abnormal functionalities are highlighted in red 
(Hanahan D, Weinberg RA, 2000).  
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Table 1.1: Kinases and Disease: Alterations in the activation of some kinases are shown 
together with diseases that occur. (modified from Fabian et al. 2005 and Cell Signaling 
http://www.cellsignal.com/reference/kinase_disease.html) 
 
Name Molecular Basis Group Disease Type 
ABL1 Translocation TK Cancer 
ACTR2B Mutation TKL Development 
AKT1 Amplified, Overexpression, and Activated AGC Cancer 
AKT2 Amplified, Overexpression, and Mutation AGC Cancer and Diabetes 
ALK Translocation TK Cancer 
ALK1 (ACVRL1) Mutation TKL Cardiovascular 
ANPalpha (NPR1) SNP and Expression RGC Hypertension 
ARG (ABL2) Translocation and Expression TK Cancer 
ATM Loss-of-function mutation Atypical CNS and Cancer 
ATR 
Mutation and Splice-Change Atypical Cancer,Development, 
andVirology 
AurA Amplified, Overexpression, and SNP Other Cancer 
AurB Overexpression Other Cancer 
Axl Overexpression TK Cancer 
B-RAF 
Gain-of-function mutation and Loss-of-
function mutation 
TKL Cancer 
BCR Translocation Atypical Cancer 
BMPR1A Loss-of-function mutation TKL Cancer 
BMPR2 Loss-of-function mutation TKL Cardiopulmonary 
BRD4 Translocation Atypical Cancer and Virology 
BRK Overexpression TK Cancer 
BTK Loss-of-function mutation TK Immunity andCancer 
BUB1 Loss-of-function mutation Other Cancer 
BUBR1 (BUB1B) Mutation and Overexpression Other Cancer 
CDC2 (CDK1) Activated and Splice-Change CMGC Cancer 
CDK2   CMGC Cancer 
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CDK4 
Activated, Gain-of-function Mutation, 
Amplified, and Methylation 
CMGC Cancer 
CDK6 Over expression and Translocation CMGC Cancer 
CDK9 
Expression CMGC Viral 
infection andCardiova
scular 
CHK1 Mutation CAMK Cancer 
CHK2 Mutation CAMK Cancer 
CK1epsilon 
(CSNK1epsilon) 
SNP, Mutation, and Loss-of-heterozygosity CK1 Behavior andCancer 
CK2alpha1 and 
CK2alpha2 
(CSNK2alpha1/2) 
Over expressionand Activated Other Cancer,Neurodegener
ation, and Circadian 
Rhythm 
COT/TPL2 
Over expression,Amplified, andMutation STE Cancer andInflammati
on 
CTK/MATK Overexpression TK Cancer 
CYGD (GUCY2D) Mutation RGC Vision 
CYGF (GUCY2F) Mutation RGC Cancer 
DAPK1 Methylation andExpression CAMK Cancer and Epilepsy 
DMPK1 Mutation AGC Neurodegeneration 
DNAPK Mutation Atypical Cancer 
EGFR 
Amplified,Overexpression, and Gain-of-
function Mutation 
TK Cancer 
EphA1 Expression TK Cancer 
EphA2 Overexpression TK Cancer 
EphA3 (HEK) Mutation TK Cancer 
EphB2 Overexpressionand Mutation TK Cancer 
EphB4 (HTK) Overexpression TK Cancer 
Erk5 (BMK1) 
Expression CMGC Cancer andCardiovasc
ular 
FAK (PTK2) Overexpression,Amplified, andActivated TK Cancer 
FER Expression TK Cancer 
FES Mutation andTranslocation TK Cancer 
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FGFR1 
Mutation andTranslocation TK Development andCan
cer 
FGFR2 
Mutation andAmplified TK Development andCan
cer 
FGFR3 
Gain-of-function 
Mutation andTranslocation 
TK Development andCan
cer 
FGFR4 SNP TK Cancer 
FGR Amplified TK Cancer 
FLT1 (VEGFR1) Methylation andOverexpression TK Cancer 
FLT4 (VEGFR3) Activated andLoss-of-function Mutation TK Lymphangiogenesis 
FMS (CSF1R) Mutation TK Cancer 
GSK3alpha and 
GSK3beta 
SNP andActivated CMGC Neurodegeneration,Di
abetes,Cardiovascular
, andCNS 
HGK (ZC1) Overexpression STE Cancer 
HIPK1 Overexpression CMGC Cancer 
HIPK2 Loss-of-heterozygosityand Expression CMGC Cancer 
Her2 (ErbB2) Amplified andOverexpression TK Cancer 
Her3 (ErbB3) Overexpression TK Cancer 
Her4 (ErbB4) Expression TK Cancer 
IGF1R 
Mutation, SNP, andOverexpression TK Cancer, Growth, 
and Longevity 
ILK Overexpression TKL Cancer 
IRAK2 
Mutation TKL Cancer andInflammati
on 
IRAK4 Mutation TKL Infection 
JAK1 Mutation andActivated TK Cancer 
JAK2 Translocation TK Cancer 
JAK3 Loss-of-function Mutation TK Immunity 
JNK3 Expression CMGC Cancer and CNS 
KDR (FLK1, VEGFR2) Mutation TK Cancer 
KIT 
Gain-of-function Mutation, Loss-of-
function Mutation, andActivated 
TK Cancer andDepigment
ation 
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LATS1 Methylation,Expression, andMutation AGC Cancer 
LATS2 Expression AGC Cancer 
LKB1 (STK11) Loss-of-function Mutation CAMK Cancer 
LYN Activated TK Cancer 
MER Loss-of-function Mutation TK Vision 
MET 
Gain-of-function Mutation,Overexpression, 
and Translocation 
TK Cancer 
MISR2 (AMHR2) Mutation TKL Reproduction 
MKK3 (MAP2K3) Mutation andDeleted STE Cancer 
MKK4 (MAP2K4) Loss-of-function Mutation andDeleted STE Cancer 
MLK4 Mutation TKL Cancer 
MST4 Overexpression STE Cancer 
MYO3A Mutation STE Sensory 
NEK2 Overexpression Other Cancer 
NEK8 Overexpression Other Cancer and Renal 
PAK3 Loss-of-function Mutation STE Cognition 
PAK4 Overexpression STE Cancer 
PDGFRalpha 
Translocation,Deleted, andMutation TK Cancer andDevelopm
ent 
PDGFRbeta Translocation andOverexpression TK Cancer 
PEK (PERK) Loss-of-function Mutation Other Diabetes 
PHKgamma2 Loss-of-function Mutation CAMK Metabolism 
PIM1 
Translocation,Overexpression, 
and Mutation 
CAMK Cancer 
PINK1 
Mutation andExpression Other Neurodegenerationan
d Cancer 
PKCalpha 
Mutation,Deleted,Overexpression, 
and Activated 
AGC Cardiovascular andCa
ncer 
PKCbeta SNP AGC Diabetes andCancer 
PKCdelta 
Expression AGC Cancer,Cardiovascula
r, andCNS 
PKCepsilon Amplified andMutation AGC Cancer,Cardiovascula
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r, andCNS 
PKCgamma 
Mutation AGC Neurodegenerationan
d Pain 
PKR (PRKR) 
Mutation,Expression, andActivated Other Cancer,Neurodegener
ation, and Virology 
PLK1 Expression Other Cancer 
PRKX Translocation AGC Reproduction 
PRKY Translocation AGC Reproduction 
RAF1 (c-Raf) Amplified TKL Cancer 
RET 
Loss-of-function Mutation, Gain-of-
function Mutation, andTranslocation 
TK Cancer andDevelopm
ent 
RHOK Loss-of-function Mutation AGC Vision 
RNAseL Mutation Other Cancer and Virology 
RON Overexpressionand Splice-Change TK Cancer 
ROR2 Mutation TK Development 
ROS Translocation TK Cancer 
RSK2 (RPS6KA3) Loss-of-function Mutation AGC Development andCNS 
SGK1 
Expression AGC Diabetes, Cancer, 
and Cognition 
SRC Mutation,Overexpression, and Activated TK Cancer 
SYK Methylation andSplice-Change TK Cancer and Allergy 
TGFbetaR1 (ALK5) SNP TKL Cancer 
TGFbetaR2 
Loss-of-function Mutation TKL Cancer,Development, 
andFibrosis 
TIE2 (TEK) 
Mutation andOverexpression TK Angiogenesis andCan
cer 
TRKA (NTRK1) Mutation andTranslocation TK Cancer and Sensory 
TRKB (NTRK2) Mutation TK Cancer 
TRKC (NTRK3) Translocation andMutation TK Cancer 
TYRO3 (SKY) Overexpression TK Cancer 
WNK1 Intronic Mutation Other Hypertension 
WNK4 Mutation Other Hypertension 
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eEF2K (CaMKIII) Overexpressionand Activated Atypical Cancer 
p38  
  CMGC Cancer andInflammati
on 
p70S6K (RPS6KB1) Overexpressionand Amplified AGC Cancer andDiabetes 
 
 
 
 
 
1.3.2 Kinase Inhibitors 
 
Therapeutic agents that are molecularly targeted have been used since 1990s 
in clinical practice. Majority of these therapeutic agents target receptor tyrosine 
kinases (RTKs)  such as but not limited to lapatinib, erlotinib, imatinib that inhibit 
HER2, EGFR and KIT respectively (Table 1.2) (Slamon et al, 2001; Paez et al, 2004; 
Lynch et al, 2004; Demetri et al, 2002; Kataoka et al, 2001). Kinase inhibitors have a 
very important advantage when compared to cytotoxic drugs having DNA synthesis 
inhibition activity. Kinase inhibitors have low side effects and produce very low 
levels of toxicity (exception trastuzumab) (Novak C, 2004). Therefore, there are 
ongoing studies for the characterization and development of new novel kinase 
inhibitor derivatives against new targets, with higher activity and efficacy.  
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Table 1.2: Some of the clinically used or candidate protein kinase inhibitors 
(taken from Fabbro et al, 2002) 
 
 
 
There is a significant obstacle for the development of effective therapeutic 
agents for kinase inhibition: selectivity and target site. Producing small-molecule 
inhibitors that disrupt ligand binding (for RTKs) or protein-substrate interaction was 
shown to be ineffective (Burke et al, 1997; Sharma et al, 2002; Fabbro et al, 2002). 
Therefore, best potential strategy for drug discovery is to target the catalytic site by 
inhibitory molecules that are ATP competitive. Still there are two important 
problems to solve: membrane penetration and selectivity. In most of the molecules 
developed, penetration is shown to be prevail however, selectivity still remains to be 
hard to overcome (Davies et al, 2000; Fabbro et al, 2002). 
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1.4. Thiazolidine Compounds 
With the improvements in proteomics in recent years, huge interest has been 
emerged for the development of anticancer drugs (Li et al, 2011).  This huge interest 
caused the establishment of chemogenomics which is a screening field for libraries 
of small-molecules in order to investigate functionalities of proteins and find 
candidates for drugs (Li et al, 2007). In a previous study, a set of anticancer drug 
candidates was produced. The aim was to create an agent with potential to induce 
apoptosis in human cancer cell lines. 
 Some previous studies showed that molecules with thiazolidine have 
cytotoxic activity in various cancer cells compared to normal cells (Li et al, 2011; Li 
et al, 2007; Gududuru et al, 2005). Thiazolidines belong to the group of heterocyclic 
organic compounds. They contain 5-membered ring that is saturated and there is a 
thioether group inside this ring at position 1 together with an amine group at position 
3. There are many commercial drugs that contain thiazolidine being the most famous 
as penicillin. On the other hand, in another study some thiazolidine-diones were 
shown to be inhibitors of protein tyrosine kinases such as EGFR or Src (Geissler et 
al, 1990).  
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CHAPTER 2. OBJECTIVES AND RATIONALE 
According to the statistical analysis, in 2007, 13% of the human deaths all 
around the world was caused by cancer and every day the rate of cancer caused death 
is rising (Jemal et al, 2011). Therefore, scientists make a lot of effort to the field of 
cancer research. There are many aspects of cancer research however one of the 
ultimate goals is the development of anti-cancer therapeutic agents with high efficacy 
but low side-effects.  
Due to the fact that protein-protein interactions are vital members of 
biological processes, development of molecules that can inhibit abnormal protein 
interactions is of ultimate importance for anti-cancer studies (Arkin et al, 2004). The 
main aim of this thesis is to identify anti-cancer small molecules with cytotocxic 
activities targetting specific cellar pathways.  
The first group of molecules which were studied during this thesis was plant-
derived small molecules from digitalis ferruginea provided by Prof. Dr. Ihsan Calis. 
As previously stated cardiac glycosides are steroid-like compounds and include 
commonly known therapeutics such as digitoxin, digoxin and ouabain (Figure 1.1). 
In previous experiments, it was shown that digitoxin, digoxin or oubain induce 
apoptosis in cancer cell lines and they are non-toxic against normal cells (Racker et 
al, 1983; McConkey et al, 2000; Ramiez et al, 2007). Most of the previous 
experiments were conducted on fragments derived from Digitalis lanata or davisiana, 
however there are no studies on molecules derived from digitalis ferruginea. Thus 
our objective was to examine pure molecules obtained by fractional extraction of of 
digitalis ferruginea and find the ingredient that has the cytotoxic activity in cancer 
cell lines and induce apoptosis in these cells. 
Most of the therapeutic agents developed and in use right now are targeted 
against protein tyrosine kinases (Slamon et al, 2001; Paez et al, 2004; Lynch et al, 
2004; Demetri et al, 2002; Kataoka et al, 2001). There are two reasons for this, first, 
protein kinases play inevitably significant role in cancer formation and progression. 
Second, kinase inhibitors have fairly low toxicity to normal cells and low side effects 
(exception trastuzumab) (Novak C, 2004). Therefore, one of our aims in this project 
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was to examine the kinase inhibitor derivatives synthesized by Prof. Dr. Birsen 
Tozkoparan. Our ultimate aim was to find the molecules with highest cytotoxicity 
with drugable IC50 values and to confirm that they are actiong on protein kinases. 
Then we showed their mechanism of cell death and the pathway that they interfere 
with. Finally, we would have small-molecule tyrosine kinase inhibitors with 
anticancer activity and these molecules would be candidates for anti-cancer 
therapeutics. 
On the other hand, we had small molecules with thiazolidine ring. In previous 
studies, it was shown that molecules with thiazolidine ring have anti-cancer activities 
(Li et al, 2011; Li et al, 2007). Thus, in addition to the kinase inhibitor derivatives, 
we tested the cytotoxic activity of some molecules with thiazolidine ring. Our 
expectation was to find some molecules with cytotoxic activity in cancer cell lines 
and that would induce apoptotic cell death. 
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CHAPTER 3. MATERIALS AND METHODS 
   
3.1. MATERIALS 
 
3.1.1 General reagents 
Most of the reagents and chemicals used including but not limited to ethanol 
and methanol, bovine serum albumin (BSA) were purchased from Sigma-Aldrich 
(St. Louis, USA) and MERC (Darmstadt, Germany). Bradford reagent for protein 
quantification was obtained from Sigma (St. Louis, MO, USA). Ponceau S and 
Dimethyl sulfoxide (DMSO) were from AppliChem Biochemica (Darmstadt, 
Germany). Trichloroacetic acid is purchased from MERC (Schucdarf, Germany). 
ECL kit, used for western blot chemiluminesence analysis, was obtained from 
Amersham Pharmacia Biotech Ltd. (Buckinghamshire, UK). Sulforhodamine B 
(SRB) sodium salt was purchased from Sigma Aldrich. Tris used for the preparation 
of 10mM TBS was obtained from Amresco (USA). Hoechst stain was purchased 
from Sigma Aldrich. Phosphatase inhibitor cocktail (PhosStop) and Protease 
inhibitor cocktail tablet (complete EDTA free) were obtained from Roche Applied 
Sciences. RNaseA used in FACS was purchased from Fermentas and propidium 
iodide was from Sigma Aldrich. Software used for FACS analysis, CellQuest was 
purchased from Becton Dickinson. 
 
3.1.2 Tissue Culture Reagents and Materials: 
Dulbecco's Modified Eagle Medium (DMEM), fetal bovine serum (FBS), 
non-essential amino acid (NEAA), penicillin/streptomycin solution, tyripsin and 
1xPBS (CaCl2 , MgCl2 free) were purchased from GIBCO (Invitrogen, Carlsbad, CA, 
USA). Flasks, petri-dishes, cell plates, serological pipettes that were used in cell 
culture were supplied from Corning Life Sciences  
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3.1.3 Antibodies: 
Antibodies were purchased from different companies, which are all listed in 
Table 3.1. Their working dilutions are also indicated in the Table 3.1. 
 
Table 3.1: Antibody list: All antibodies used are listed together with their working 
dilutions and incubation periods.     
Name working dilution Incubation period 
and type 
company name 
α-actin (goat 
polyclonal) 
1:500 2 hours, RT Santa Cruz 
Anti-goat HRP 1:5000 1 hour, RT Santa Cruz 
Anti-rabbit HRP 1:5000 1 hour, RT Sigma Aldrich 
PARP (rabbit 
monoclonal) 
1:200 2 hours, RT Cell Signaling 
 
 
3.1.4 Western Blot, Electrophoresis, Kinase assay, Spectrophotometer and 
Microplate Reader for SRB Assay 
Spectrometer used for Bradford Assay was Beckman Du640, purchased from 
Beckman Instruments Inc. (CA, USA). Kinase Assay reagents (Kinase-Glo Plus 
Luminescent Kinase Assay) were purchased from Promega (USA). The Reporter 
Microplate Luminometer Reader used for Kinase Assay was obtained from Turner 
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Bio-Systems (Sunnyvale, USA). Microplate reader used for SRB assay was obtained 
from Beckman Instruments. 
Western Blot reagents such as NuPAGE pre-cast 12% and 10% Bis-Tris mini 
gels, running buffers (MOPS,MES), transfer buffer, electrophoresis tank, transfer 
equipment, 4X sample loading buffer, 10X denaturing agent and antioxidant were 
from Invitrogen. Power supplies Power-PAC200 and Power-PAC300 were from Bio-
Rad Laboratories (CA, USA).  
 
3.2 SOLUTIONS AND MEDIA 
 
3.2.1 Cell culture solutions 
DMEM growth medium working solution    10% FBS, 1%  
                                                                                    penicillin/streptomycin,  
                                                                                    1% non-essential amino                            
                                                                                    acid. Stored at 4
o
C. 
 
 
3.2.2 Western blot and Protein lysis solutions and buffers 
 
NP-40 lysis buffer 150 mM NaCl, 50 mM                   
 TrisHCl (pH 7.6), 1% NP-40, 
0.1% SDS, 1x protease inhibitor 
cocktail, 1x phosphatase inhibitor 
cocktail in double-distilled water. 
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 10X Tris buffered saline (TBS) 12.2 g Trisma base, 87.8 g   
 NaCl in 1 liter ddH2O, pH 7.4. 
 
 TBS-tween (TBS-T) 0.1% Tween-20 was  
 dissolved in 1x TBS. 
 
 Ponceau S  0.1% (w/v) Ponceau, 5 %  
 (v/v) acetic acid in  
 double-distilled water. 
 
Blocking solution 5% (w/v) non-fat dry  
 milk/bovine serum  
 albumin in 0.2% TBS-T. 
 
 
3.2.3 Cell cycle analysis solutions    
Propidium Iodide staining solution    50 μg/mL propidium iodide, 0.1  
mg/mL RNaseA and 0.05% 
TritonX-100 in 1X PBS. 
 
3.2.4 Kinase Assay solutions 
Kinase-Glo reaction buffer                             40mM Tris-HCl pH7.6,  
20mM MgCl2, 0.1mg/ml BSA in 
double-distilled water. 
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Kinase-Glo plus reagent buffer     Mix 1 vial Kinase-Glo plus  
Substrate and 10ml Kinase-Glo  
plus buffer than take 1ml 
aliquots. For each reaction 50μl 
of this buffer is mixed with 50 μl 
sample solution in Kinase-Glo 
reaction buffer.  
3.2.5  Sulphorhodamine B assay solutions 
SRB stain solution             0.04gr SRB stain in 10ml 1%  
            acetic acid solution. 
 
10% TCA solution                   100% TCA was diluted into 10%  
in cold  ddH2O. 
 
10mM TBS                                                      0.6gr Tris was dissolved in  
1000ml cold ddH2O. 
 
 
 
3.2.6 Immunofluorescence staining: 
Hoechst stain stock solution    300μg/ml Hoechst dissolved in  
ddH2O and stored at +4
o
C. 
 
Hoechst stain working solution   1μg/ml Hoechst diluted from  
300μg/ml stock in 1x PBS. 
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3.3 METHODS: 
 
3.3.1 Cell lines and growth conditions 
Human liver cancer cell lines (Huh7, Mahlavu, Focus, HepG2, Hep3B), 
human breast cancer cell line (MCF7) and human colon cancer cell line (HCT116) 
were cultivated in complete growth medium composed of DMEM, with 10% FBS, 
1% NEAA and 1% P/S. All cell lines were incubated in 37 °C, 5% CO2, 95% air 
containing incubators. For the sub culturing of the cells, when they reached %75-
%80 confluence, they were washed twice with 1xPBS after aspirating the growth 
medium and then trypsin-EDTA solution was applied. Then the cells were 
resuspended in fresh growth medium and aliquots of appropriate concentration (sub 
culturing ratio between 1:6 to 1:10 depending on the cell type) was transferred into 
new culture dishes with fresh complete growth media.  
For the experiments that require a defined number of cells, after 
trypsinization and resuspension of the cells in fresh growth medium, hemocytometer 
was used to count the cell number.  
Before usage, all solutions and media were warmed to 37
o
C from 4
o
C. 
 
3.3.2 Thawing of the cell lines: 
All cell lines used are stored in liquid nitrogen. Before usage, one vial of the 
cell line of interest is taken out of the tank and directly put into 37
o
C water bath for 
1-2 minutes so that the cell solution starts to thaw. When the outer layer of the 
solution is thawed, the whole cell suspension is resuspended in 5ml warm fresh 
growth medium, moved into a 15ml falcon tube and centrifugated at 1200rpm, +4
o
C, 
for 3 minutes. After the supernatant is aspirated, cell pellet is resuspended in 10ml 
warmed fresh growth medium and transferred into 100mm culture dish. Then the 
media of the cells are refreshed after 24hr incubation in 37 °C, 5% CO2, 95% air 
containing incubators. 
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3.3.3 Storage of the cell lines: 
After cells were harvested by trypsinization, trypsin was neutralized with 
growth medium, which contains FBS. Then the cells were centrifugated at 1500rpm 
for 5 min, +4°C. The cell pellet was then resuspended in freezing medium of 
10%DMSO, 20%FBS and 70% complete DMEM in a concentration of 4x10
6
 
cells/ml. Finally, 1 ml of the cell solution was transferred into 1ml screw capped-
cryotubes. They are left in -20°C for 1 hr and then transferred into -80°C. 24hr later, 
they were located into liquid nitrogen tank. 
 
3.3.4 Crude total protein extraction: 
Cancer cell lines of defined cell count (from 100.000 to 250.000) were 
cultured into 100mm culture dishes. After 24hr incubation, growth medium was 
aspirated and the cells were washed twice with 1xPBS. Then new growth medium 
containing the corresponding small molecule inhibitor (or DMSO as control) 
concentration was applied on the cells. Then in a time dependent manner (12hr, 24hr, 
36hr, 48hr time periods), the inhibitor containing medium (or DMSO as control) was 
aspirated and ice-cold PBS was applied. Finally cells were scraped using rubber 
scrapers.  Cell suspensions were transferred into 15ml falcon tubes and centrifuged 
for 1200rpm 5min +4°C. Then supernatant was aspirated and cells were resuspended 
in 2ml ice-cold PBS and centrifuged for 1200rpm 5min +4°C once again. Finally, the 
supernatant was discarded and cell pellets were frozen in liquid nitrogen and stored 
in -80°C.   
For the production of protein lysates, lysis buffer (150mM NaCl, 50mM Tris-
HCl pH=7.6, 1% NP-40, 0.1% SDS, 1x Protease inhibitor cocktail and 1x PhosStop) 
is applied to the cell pellets in twice the amount of the pellet. After mixing the pellets 
by vortex, they were incubated on ice for 45min (mixing by vortex every 5 min). In 
case of viscosity, samples are sonicated (if no viscosity, this step is skipped). After 
centrifugation, the samples at 13,000rpm for 15-20min at +4°C, the supernatant was 
transferred into new eppendorphs and stored at -20°C. 
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3.3.5 Western Blotting: 
 The quantification of the protein in lysates, the Bradford protein assay was 
conducted. BSA in solutions with known concentrations was used as reference for 
standard curve of OD595. The protein concentrations of cell lysates were calculated 
with respect to the standard curve.  Then equal amounts of cell lysates (20ng-50ng of 
protein) were solubilized with 1x loading dye, SRA (or DTT) and then water is used 
to fill the total solution volume to 15ul or 25ul. Then the lysates were denatured for 
10 min in 70°C following the incubation of lysates on ice for 2 min. Then the 
samples were spinned down and loaded into the gel. 
NuPAGE NOVEX pre-cast gel system was used for all western blot analysis 
procedures according to the manufacturer’s protocol. 12%, 10% Bis-Tris gels were 
used. Depending on the protein length MOPS or MES running buffer was used. In 
correspondence with the manufacturer’s protocol, 10%methanol was added to the 
transfer buffer.  
After electrophoresis and the transfer of the proteins from the gel to 
nitrocellulose membrane (30V, 90min) the membrane was incubated overnight in 
blocking solution (%5milk powder in 1xTBS-T(0.1%tween)) at +4°C. Then the 
membrane was treated with primary antibody (1hr-2hr) at room temperature. 
Washing off the membrane 4 times (for 5min, 10min, 10min,and 5min) with 1xTBS-
T(0.1%tween) solution was followed by the treatment of the membrane with 
secondary antibody (1hr-90min) at room temperature. Finally after washing the 
membrane once more, chemiluminesence was performed with ECL+ kit according to 
the manufacturer’s protocol. The emmition of chemiluminesence was captured on X-
ray film with different exposure times. 
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3.3.6 Kinase Assay: 
Kinase-Glo plus luminescence kinase activity assay (Promega) was 
performed according to manufacturer’s protocol.  
First the Kinase-Glo reaction buffer (40mM Tris-HCl pH7.6, 20mM MgCl2, 
0.1mg/ml BSA) was placed into the wells of a 96-well Elisa plate. Then lysates 
(25μg protein concentration) (protein quantification was done by Bradford assay) 
were placed into the wells. The total volume of lysate and kinase reaction buffer is 
50μl. Then 50μl Kinase-Glo reagent (Kinase-Glo plus substrate+Kinase-Glo plus 
Buffer) was applied. After 10min dark incubation at room temperature, the 
luminescence was detected in luminometer. If kinase activity is diminished, ATP 
concentration increase and so will the luminescence .  
 
3.3.7 NCI-60 Sulphorhodamine B (SRB) assay: 
Human cancer cell lines of breast, colon and breast (range of 2000cell/well to 
5000cell/well) were plated into 96-well plates in 200μl of media. After 24hr 
incubation period of cell lines in 37 °C incubators containing 5% CO2, 95% air, one 
plate for each cell line was fixed using 50μl 10% ice-cold trichloroacetic acid (TCA) 
(time-zero plate representing the behavior of the cells at the time of drug treatment) 
and in the same time compounds of interest (compounds are solubilized in DMSO) 
were applied to the cells in desired concentrations and diluted by serial dilution. 
Following drug treatment, the cells were incubated in 37 °C incubators for 24hours, 
36hours or 72hours.  In order to terminate the incubation period, cells were fixed 
with 50μl 10% ice-cold TCA and incubated 1hr in dark at +4oC. After washing TCA 
with ddH2O repeatedly, the plates were left to dry. Finally, 50μl 
0.4%sulphorhodamine B (SRB) solution in 1% acetic acid was used to stain the 
plates. Following the 10min dark incubation period, 1% acetic acid is used to discard 
excess dye. For the quantification of the bound stain, SRB is solubilized using 200μl 
of 10mM Tris-Base. Finally, the OD values were obtained at 515nm wavelength by 
using Elisa reader.  
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3.3.8 Real time cell growth surveillance by cell electronic sensing (xCelligence): 
In order to eliminate background noise, into each well of the 96-well E-plate 
(Roche Applied Sciences) 50μl growth media was applied and the absorbance was 
read. Then, human cancer cell lines (range from 1000cell/well to 5000cell/well in 
150μl) were plated into E-plate. In real-time cell electronic sensing RT-CES 
(xCelligence) the proliferation curve of the cells were obtained. In the first 24hour 
period, in every 30min, the cell index values were detected (9). After 24hr 
incubation, growth medium is aspirated and 100μl fresh growth medium was applied. 
Then the cells were treated with the compounds of interest in the indicated 
concentrations. In the first 24hr of drug treatment, cell index values were detected for 
every 10 min (fast-drug response) then it changes to every 30 min (long-term drug 
response). Detected cell index values symbolizes the impedance measurements. By 
calculating CIdrug/CIdmso, the inhibitory effect of the compounds on the cell lines were 
calculated in response to DMSO control (10). 
 
3.3.9 Immunofluorescence staining: 
Autoclaved coverslips were placed into 6-well plates and human cancer cell 
lines were inoculated into these 6-well plates (range 30.000-100.000 cell/well) in 2ml 
growth medium. 24hr later, growth medium was aspirated and 1.5ml fresh growth 
medium that contains the compounds of interest at indicated concentrations was 
applied to cells. After 24hr, 48hr or 72hr incubation period, the cells were washed 
once with ice-cold 1xPBS and fixed with 100% ice-cold methanol for 10min. Then 
excess methanol was discarded by washing once with ice-cold 1xPBS. Then 1μg/ml 
Hoechst stain (dissolved in PBS) was applied to the cells and left for dark incubation 
5min. Finally destaining was established in ddH2O for 10 min.  
After the staining process, coverslips were mounted onto slides with glycerol 
and cells were observed under fluorescent microscope and pictures were taken. 
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3.3.10 Fluorescence-activated cell sorting (FACS) analysis: 
Human cancer cell lines of interest were inoculated into 100mm culture dish 
(100.000-200.000 cell/dish) in 6ml growth medium. 24hours later, growth medium 
was replaced by the starvation medium (1%FBS, 1%P/S, 1%NEAA in DMEM). 
After cells were incubated in starvation medium for one more day, drug treatment 
was applied in growth medium. At the same time, time zero plates were fixed.  
For fixation of the cells, first of all swimming cells were collected in 15ml 
falcon tubes. Then remaining cells inside the culture dish were washed once with 
1xPBS and trypsinized. These trypsinized cells were then harvested together with 
previously collected swimming cells. The cell suspension was then centrifuged for 
5min, at 1200rpm. Supernatant was discarded and cell pellet was resuspended in 5ml 
1xPBS. Once again the cell suspension was centrifuged for 5min, at 1200rpm and 
supernatant was discarded. Finally pellet was resuspended in 1ml ice-cold 1xPBS 
and fixed by addition of 2.5ml, 100% EtOH (final concentration was 70%) drop wise 
while mixing by vortex meanwhile. Then the samples were stored at +4
o
C.  
Before analyzing the samples with FACS machine, cell pellet was 
resuspended in 500μl Propidium iodide (PI) solution (25μl PI, 5μl RNaseA (10mg/ml 
stock), 0.25μl Tritron-X-100, 469.75μl ice cold 1xPBS) and incubated at 37oC (dark) 
for 40min. Afterwards, 3ml 1xPBS was added onto the samples and centrifuged at 
150rpm for 5min, +4
o
C. Supernatant was discarded and pellet was resuspended in 
500μl 1xPBS and loaded to the machine for FACS analysis.  
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CHAPTER 4. RESULTS 
 
4.1 Digitalis Ferruginea 
 
4.1.1 Cytotoxic activity analysis of all 6 ingredients of Digitalis Ferruginea 
Initially, the cytotoxic activity of the Digitalis Ferruginea ingredients 
Lanatoside A, Lanatoside C, Glucogitorosid, Ferruginoside A, Lugrandoside and 
Ferruginoside B was analyzed using NCI-60 SRB assay as described in the methods 
part. Molecules were tested on liver (HUH7, MV, HepG2, Focus) cancer cell lines. 
Lanatoside A, Lanatoside C and Glucogitorosid showed significant cytotoxic effects 
on liver cancer cell lines whereas the other three agents weren’t effective (Figure 
4.1).  
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Figure 4.1: Percent cell death inhibition: Liver cancer cell lines Huh7, HepG2, Mahlavu 
and Focus were treated with Lanatoside A, Lanatoside C, Glucogitorosid, Ferruginoside A, 
Lugrandoside and Ferruginoside B for 72h. NCI60 SRB analysis was applied as explained in methods. 
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Furthermore, the time-dependent cytotoxic activities of three compounds 
Lanatoside A, Lanatoside C and Glucogitorosid were investigated using the cell 
electronic assay xCELLigence in real-time. As seen in Figure 4.2 and 4.3, all three 
compounds have irreversible growth inhibitory effect on both liver cancer cell lines 
Huh7 and Mahlavu for 72 hrs. The cytotoxic effects of the compounds are highest in 
8hr incubation period and it decreases as the incubation time increases to 72 hours. 
On the other hand, the inhibitory effect of the compounds in Huh7 is relatively lower 
than Mahlavu at same concentrations. This also confirms the SRB assay result that 
IC50 value of Huh7 is higher than mahlavu and percent inhibition of the compounds 
at constant concentration is higher in mahlavu (Figure 4.1, 4.2 and 4.3).   
 
4.1.2 Morphological effect of the compounds 
After showing that three compounds of the total 6 have high cytotoxic 
activity on cancer cell lines, we wanted to investigate the death mechanism that they 
trigger. Previous data show that cardiac glycosides induce apoptosis in a tissue-
specific manner (Moss, 1998; Winnicka et al 2006). On the other hand, in some other 
study it was mentioned that cardiac glycosides are also activators of autophagy 
pathway (Hundeshagen et al, 2011). Therefore, in order to investigate the death 
mechanism the compounds induce, Huh7 and Mahlavu cells were treated with 
Lanatoside A, Lanatoside C and Glucogitorosid and observed under inverted 
microscope. 
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Figure 4.4: Morphological effect of Cardiac glycosides Lanatoside A, 
Lanatoside C and Glucogitorosid on Huh7 and Mahlavu human liver cancer 
cell lines (10x). Cancer cell lines were treated with 2µM of the corresponding molecule. Then 
photographs of the cells were taken with inverted microscope after 24 and 48hours of incubation. 
DMSO treated cells were used as control.  
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As seen in Figure 4.4, cells treated with all three compounds showed 
apoptotic morphological changes. Shrinking cells were observed as well as cells in 
“horse-shoe” structure. Most of the cells observed were in a circulated structure.  
 
 
Figure 4.5: Hoechst staining of Huh7 cell lines: Morphological effect of a) Lanatoside A, 
b) Lanatoside C, c) Glucogitorosid d) DMSO at 2μM concentrations were observed on Huh7 cell 
lines. Human cancer cell lines were inoculated on coverslips in the confluency of 60-70% and 
incubated 24hr at 37
o
C. Then Huh7 cells were treated with corresponding molecules for24hr and 
Hoechst staining was applied.  
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After observing the cells under inverted microscope, we wanted to confirm 
the presence of apoptotic induction by Hoechst staining. For this purpose, human 
liver cancer cell line Huh7 was treated with three compounds and stained with 
Hoechst. Then cells were observed under fluorescent microscope. As seen in Figure 
4.5, Hoechst staining showed condensed nuclei that indicated apoptotic cells in 
treated samples. Whereas in Huh7 cell group treated with DMSO, no apoptotic cells 
were present. This also confirmed that Lanatoside A, Lanatoside C and 
Glucogitorosid induce apoptosis in liver cancer cell lines. 
 
4.1.3 Cell cycle arrest caused by Lanatoside A, Lanatoside C and Glucogitorosid 
Decrease in the proliferation of the cells and induction of cell death points the 
presence of cell cycle arrest. Therefore, we used propidium iodide labeling, which is 
a fluorescence molecule that interacts with DNA (Senturk et al, 2010). The 
progression of cell cycle was observed in propidium iodide labeled Huh7 and 
Mahlavu cell lines treated with corresponding compounds using flow cytometry. As 
seen in Figures 4.6 and 4.7, cells treated with Lanatoside A, Lanatoside C and 
Glucogitorosid all showed a slight increase in G2/M phase when compared to DMSO 
control. 
Normally, healthy well-differentiated HCC cell lines would be 60-70% in G1 
phase, 20% in S phase, and 20% in G2-M phase. However, in treated cells, G2/M 
phase increased to 30-35% and G1 phase decreased to 40-50% (Figure 4.6).  
Mahlavu, which is a poorly differentiated HCC cell line, also showed similar results 
in which G2/M phase cells showed an increase when compared to DMSO control 
(Figure 4.7). 
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Figure 4.6: Cell cycle analysis after treatment with a) DMSO, b) Lanatoside A, c) Lanatoside 
C, d) Glucogitorosid, in Huh7 cell lines. In part e) the graphical analysis of cell cylce is shown. In 
parts a,b ,c and d, the peak at 200 FL2-A represents 2N cells (G1) and the peak at 400 represents 4N 
cells (G2). The peak in between represents S-phase cells. During gating >4N cells were excluded since 
those didn’t show any variation between control and treated cell groups. FACS analysis was done as 
explained in the methods part. All drugs are applied at 2µM concentration. 
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g) 
 
Figure 4.7: Cell cycle analysis after treatment with a) DMSO (for Lanatoside A), b) 
Lanatoside A, c) Lanatoside C, d) Glucogitorosid, e) DMSO (for Lanatoside C and Glucogitorosid) in 
Mahlavu cell lines. In part f) and g) the graphical analysis of cell cycle is shown. In parts a,b ,c and d, 
the peak at 200 FL2-A represents 2N cells (G1) and the peak at 400 represents 4N cells (G2). The 
peak in between represents S-phase cells. During gating >4N cells were excluded since those didn’t 
show any variation between control and treated cell groups. FACS analysis was done as explained in 
the methods part. All drugs are applied at 2µM concentration. 
 
4.1.4 Apoptosis induction by Lanatoside A, Lanatoside C and Glucogitorosid  
In the previous parts, it was shown that all three compounds causes 
morphological changes in cancer cells that represent apoptosis. Finally, we wanted to 
confirm apoptosis induction on the protein level. Thus we investigate Poly(ADP-
ribose) Polymerase (PARP) cleavage in cells treated with the compounds in response 
to DMSO control. Previously it was shown that PARP cleavage which is catalyzed 
by caspase 3 is required for apoptosis progression (Boulares et al, 1999). Therefore, 
we treated Huh7 and Mahlavu liver cancer cell lines with Lanatoside A, Lanatoside 
C and Glucogitorosid and investigated the presence of PARP cleavage by Western 
Blot analysis.  
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0h 12h24h36h48h 0h 12h24h36h48h 0h 12h24h36h48h
DMSO Lanatoside C Glucogitorosid
SUB-G1
G2
S
G1
45 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: PARP cleavage in Huh7 and Mahlavu cells treated with 
corresponding compounds: Both fragments of PARP are recognized with this antibody so in 
case of apoptosis two bands are seen. Actin was used for equal loading of the proteins. Western blot 
procedure was performed as mentioned in the methods part. All drugs are applied at 2µM 
concentration. 
 
In Figure 4.8, it can be clearly seen that Lanatoside A induces PARP cleavage 
and thus apoptosis in both Huh7 and Mahlavu cell lines in 48hr. However in 12hr 
incubation of Mahlavu cell line, PARP cleavage is hardly seen. On the other hand, 
Lanatoside C promotes PARP cleavage both in 12hr and 48hr in Mahlavu cell line. 
In addition, it promotes PARP cleavage in Huh7 as well. Finally, Glucogitorosid can 
induce PARP cleavage strongly in Mahlavu cell lines in both incubation periods 
however in Huh7 cell line even in 48hr incubation cleavage is very low.  
Hence all these experiments show that cardiac glycosides Lanatoside A, 
Lanatoside C and Glucogitorosid all induces caspase-related apoptosis and cell cycle 
arrest at G2/M-phase in liver cancer cell lines. 
Actin 
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4.2 Kinase Inhibitor Derivatives 
 
4.2.1 Cytotoxic activity analysis 
Initially, the cytotoxic activities of all the candidates were analyzed using 
NCI60 SRB assay in triplicate as described in the methods part. Molecules were 
tested initially on liver (HUH7), breast (MCF7) and colon (HCT116) cancer cell 
lines. The best cytotoxic activity was observed in IBUTRI group candidates (Table 
4.1). Due to these promising results, number of carcinoma cell lines tested was 
increased in liver cancer (HepG2, Hep3B and Mahlavu). As seen in Table 4.2, 
IBUTRI group candidates showed high cytotoxic activity in micromolar 
concentrations in these liver cancer cell lines as well. 
Table 4.1: Inhibitory concentration 50 (IC50) values of the compounds: All 
compounds were tested for cytotoxic activity by means of SRB assay in triplicates for 72hours as 
explained in the methods part.  
 HUH7 MCF7 HCT116 
Molecule Name IC-50 (μM) IC-50 (μM) IC-50(μM) 
IBUTRI 33.5 17.8 39.7 
NAPTRI 43.4 124.2 20.8 
IBUTRI-nTDZ 8.1 6.6 18.6 
IBUTRI-ClTDZ 15.2 10.4 17.4 
IBUTRI-FTDZ 8.5 4.2 8.9 
NAPTRI-nTDZ 13.2 15.4 18.6 
NAPTRI-ClTDZ 9.3 9.8 8.4 
NAPTRI-FTDZ 13.7 11.9 10.8981 
4-CH3FOXAT no inhibiton no inhibiton no inhibiton 
4-CH3FOXPT no inhibiton no inhibiton no inhibiton 
4-CH3FOXAT-nTDZ 45.4 22.6 54.5 
4-CH3FOXAT-ClTDZ 39.9 27.8 51.6 
4-CH3FOXAT-FTDZ 18.8 32.7 65.1 
4-CH3FOXPT-nTDZ 19.6 14.5 18.6 
4-CH3FOXPT-ClTDZ 11.9 13.7 29.2 
4-CH3FOXPT-FTDZ 21.9 16.3 27.2 
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Table 4.2: Inhibitory concentration 50 (IC50) values of the compounds: All 
compounds were tested for cytotoxic activity by means of SRB assay in triplicates for 72hours as 
explained in the methods part. Huh7 cell treatment was repeated as a confirmatory experiment. 
 
HUH7 
IC50(μM) 
MV 
IC50(μM) 
HEPG2 
IC50(μM) 
HEP3B 
IC50(μM) 
IBUTRI 16.4 49.4  13.1  4.3  
IBUTRI-nTDZ 4.7  5.2  8.0  6.6  
IBUTRI-ClTDZ 9.2  9.2  8.3  0.1  
IBUTRI-FTDZ 8.8  6.5  8.3  6.7  
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Figure 4.9: Real-time cell growth analysis of IBUTRI compounds on Huh7 cell 
lines: Compound IBUTRI, IBUTRI-Ntdz, IBUTRI-ClTDZ and IBUTRI-FTDZ were applied on 
Huh7 cell line in 20µM and 10µM concentrations and observed for 72 hours. Cell-impedance based 
xCelligence system was used to observe the growth inhibitory effect in real-time as explained in the 
methods part. The graphs represent time-dependent effect of the compounds on both cell index and 
cell-growth. DMSO treated control cells (BLACK) were used as control and cell growth in compound 
treated was normalized to the growth in DMSO treated cells. Further normalization was performed 
according to time-zero values.   
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The time-dependent cytotoxic activity surveillance was performed for 
IBUTRI group compounds using xCelligence for Huh7 cell line. As seen in Figure 
4.9, IBUTRI shows a reversible cytotoxic effect. On the other hand, other three 
compounds have an irreversible growth inhibitory effect on Huh7 cell line during the 
time of analysis.  
 
4.2.2 Kinase Inhibitory Activity 
Kinases use ATP to phosphorylate proteins (Hanks et al, 1988). In other 
words, kinases cause decrease in the amount of ATP and increase in the amount of 
ADPs. Thus in the presence of a kinase inhibitor ATP concentration in the 
environment will not decrease since the kinase will not be able to phosphorylate any 
protein meaning that it will not use ATP. By using a Kinase Assay, which is 
luminescence based, we can determine if the molecule of interest inhibits kinase 
activation or not. The luminescence is bound to ATP so if the molecule is a kinase 
inhibitor, luminescence signal will increase.  
After choosing the IBUTRI group molecules as the most promising 
candidates, their kinase inhibitory effect had to be investigated. For this purpose, we 
used Promega KinaseGlo Assay Kit as explained in the methods part and according 
to the manufacturer’s protocol. 
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Figure 4.10:  Kinase Inhibitory effect of IBUTRI group molecules: The kinase 
activity of a) Huh7, b) Mahlavu, c) Hep3B and d) HepG2 when treated with IBUTRI group candidate 
molecules is shown in the graphs. Drug concentrations of IBUTRI, IBUTRI-nTDZ, IBUTRI-ClTDZ, 
and IBUTRI-FCL in Huh7 are as follows respectively: 32μM, 10 μM, 20μM, 16 μM. Drug 
concentrations of IBUTRI, IBUTRI-nTDZ, IBUTRI-ClTDZ, and IBUTRI-FCL in Mahlavu are as 
follows respectively: 100μM, 10 μM, 18μM, 15 μM. Drug concentrations of IBUTRI, IBUTRI-nTDZ, 
IBUTRI-ClTDZ, and IBUTRI-FCL in HepG2 are as follows respectively: 26μM, 16 μM, 16μM, 16 
μM. Drug concentrations of IBUTRI, IBUTRI-nTDZ, IBUTRI-ClTDZ, and IBUTRI-FCL in Hep3B 
are as follows respectively: 8μM, 14 μM, 0.2μM, 7 μM Staurosphorine (STS) is used as a positive 
control (0.5μM) together with Erlotinib (14μM) and Imatinib (10μM) and DMSO as a negative 
control. Bar graphs represent luminescence signal emitted by the cells. The higher the luminescence 
signal, the lower the kinase activity. Kinase Glo Assay was performed as explained in the methods 
part.  
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This experiment showed that IBUTRI-nTDZ has the highest kinase inhibitory 
effect on human liver cancer lines and IBUTRI has the lowest inhibitory effect 
(Figure 4.10). 
 
4.3 Acivity of Thiazolidine ring containing ALC 67 on cancer cell lines 
 
4.3.1 Cytotoxicity analysis 
In a previous study set of molecules with thiazolidine core was synthesized 
by Dr. Esra Onen. There were three groups of molecules: pyrimidic base containing, 
benzoyl moiety containing and N-acetylated triazoles (Esra et al, 2008). From these 
molecules a selected set of anticancer drug candidates containing thiazolidine core 
was synthesized and their cytotoxic activity was denermined by SRB method. In 
Figure 4.11, it was shown that the compounds did not have significant cytotoxic 
activity except compound ALC67, which showed a dramatic cytotoxic activity 
(Table 4.3). ALC67 is a terminal alkyne precursor of triazoles.  
After observing the high cytotoxicity of ALC67 in Huh7, MCF7 and HCT116 
cell lines, the number of cell lines analysed were increased (Table 4.3). The growth 
inhibitory effect of ALC67 also continued in these cell lines as well.  
Then, to confirm these date, we performed time-dependent cytotoxic activity 
surveillance using xCELLigence for liver (Huh7, Mahlavu, Focus), breast (Mcf7, 
Cama-1, T47D) cell lines. As seen in Figure 4.12, highest cytotoxic effect was 
observed in Huh7. Growth inhibition was almost 100% even in IC25. On the other 
hand, results of all other cell lines correlate with SRB results. IC50 concentrations 
show almost 50% inhibitions on growth of the rest of the cell lines. The only 
problematic result was in Cama-1, all concentrations caused 25% inhibition, even 
IC100. 
53 
 
Table 4.3: IC50 values of ALC67 in human cancer cell lines: Human cancer cell lines 
of liver, breast, gastric and endometrial cancer were treated with ALC67 for 72hr in triplicates and 
IC50 values were determined by means of NCI-60 SRB analysis as explained in methods part. 
TISSUE CELL LINE IC50 
Liver HEPG2 10 
HUH7 5 
MV 0.41 
FOCUS 5.47 
Breast T47D 7.62 
MCF7 5.04 
BT20 1.6 
CAMA-1 0.01 
Gastric KATO-3 0.0004 
Endometrial MFE-296 0.0027 
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Figure 4.11: Percent cell death inhibition graphs: Preliminary screen was performed on 
breast (MCF7), colon (HCT116) and liver (HUH7) cancer cell lines. Cell lines were treated with 
corresponding compounds for 72h. NCI60 SRB analysis was applied as explained in methods. 
Camptothecin was used as a positive control. 
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4.3.2 Cell cycle arrest induced by ALC67 
Furthermore, in order to investigate the consequences of ALC67 treatment in 
molecular and cellular level, we wanted to investigate the cell cycle and examine if it 
causes an arrest in cell cycle. Fluorescence-activated cell sorting analysis with 
propidium iodide revealed cell cycle arrest in ALC67 treated Huh7 cells compared to 
DMSO treated controls. 
As stated above, normally, healthy well-differentiated HCC cell lines would 
be 60-70% in G1 phase, 20% in S phase, and 20% in G2-M phase. In our data, it can 
be observed that there is an obvious increase in SubG1/G1 cells indicating an arrest 
at this point of cell cycle (Figure 4.13). 
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Figure 4.13: Cell cycle distribution analysis: Huh7 cells were treated either with DMSO 
for a) 12hr and b) 24h or with ALC67 for c)12hr and d) 24hr. e) is the graphical representation of cell 
cycle. Then cell cycle analysis was performed with FACS analysis as explained in methods part. The 
peak at 200 FL2-A represents 2N cells (G1) and the peak at 400 represents 4N cells (G2). The peak 
in-between represents S-phase cells. During gating >4N cells were excluded since those didn’t show 
any variation between control and treated cell groups. Drug concentrations were 5μM. 
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CHAPTER 5. DISCUSSION AND CONCLUSION 
 
One of the hot topics in cancer research is the development of molecules that can 
alter protein-protein interactions that are abnormally functioning in cancer cells (Arkin et al, 
2004).  
In this study, our main focus was to identify and characterize small-molecule 
inhibitors that have the potential to be anti-cancer therapeutic agent against solid human 
cancers. For this purpose, we investigated three groups of molecules. First group of 
molecules were plant-derived cardiac glycosides, and the other two were synthetic molecules 
which were designed to synthesize kinase inhibitor derivatives and thiazolidine containing 
molecules.  
Steroid-like compounds, Cardiac glycosides have been in use widely for the 
treatment of heart failures since many years (Gheorghiade et al, 2006; Hamad et al, 2007). It 
has been shown that they have inhibitory action on the activity of Na+,K+-ATPase  and 
thereby regulate the intracellular concentration of potassium, sodium directly and calcium 
ions indirectly (Kaplan JH, 2002; Newman et al, 2008;Wasserstromet al, 2005).  
In previous studies cardiac glycosides extracted from digitalis lanata were shown to 
inhibit malignant cell proliferation at nanomolar concentrations (Shiratori et al, 1967; 
Winnicka et al, 2006; Erdmann and Schoner, 1973; Pathak et al, 2000; Gupta et al 1986). 
Most of the established studies were done on the extracts of digitalis lanata and davisiana but 
not of digitalis ferrugiana. In our project, our aim was to investigate the effects of cardiac 
glycosides extracted from Digitalis Ferrugiana. Initially, we started by analyzing the 
cytotoxic activity of all Digitalis Ferrugiana extracts obtained from Prof. Dr. Ihsan Calis. As 
shown in Figure 4.1, three of the six extracts displayed high cytotoxicity to human cancer 
cell lines at µM concentations. Lanatoside A, Lanatoside C and Glucogitorosid were the 
cardiac glycoside agents of Digitalis Ferrugiana so it was not surprising to observe their high 
cytotoxicity against cancer cells. The three extracts that didn not show any cytotoxicity 
weren’t cardiac glycosides but Phenylpropanoid Glycosides. So this result correlates with the 
previous findings that cardiac glycosides alter cell proliferation (Erdmann and Schoner, 
1973; Pathak et al, 2000; Gupta et al 1986). Moreover, we demonstrated that, even when 
applied in 0.5μM, it was enough to kill all cancer cells at the end of 72hr (Figures 4.2 and 
4.3). This data also confirms their immediate and strong cytotoxicity. Thus these compounds 
are good candidates for anti-cancer therapeutics since they can be applied at nanomolar 
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concentrations, which are considered as “druggable concentration”. Moreover, in the 
literature, it was reported that cardiac glycosides cause activation of Src/EGFR and 
consequently lead to apoptosis or autophagy induced cell death (Newman et al, 2008; Xie 
and Cai, 2003; Schoner and Scheiner-Bobis, 2007 ). It was also reported that when given in 
drugable concentrations, cardiac glycosides causes proliferative arrest and apoptosis 
induction prostate cancer cell lines (Johansson et al, 2001; Haux et al, 2001). 
In order to investigate the death pathway they induce, we first examined the cells 
treated with these molecules under inverted microscope and then observed by Hoechst 
staining. In Figures 4.4 and 4.5 we can clearly demonstrate that Digitalis Ferugiana extracted 
glycosides induce apoptosis. In order to confirm the induction of apoptosis, we further 
analyzed treated cells with western blot against PARP antibody and showed  the cleaved 
PARP in treated cells but not in DMSO controls Figure 4.8. It can be clearly seen that in 
48hr, Lanatoside A can induce cleavage of PARP in both cell lines. However, in Mahlavu 
cell line, PARP cleavage is not seen in 12hr incubation period. Lanatoside C has the ability 
to induce apoptosis both in Huh7 and Mahlavu even in 12hr incubation. Finally 
Glucogitorosid induced PARP cleavage strongly in Mahlavu cell lines in both incubation 
periods. However in Huh7 cell line, even in 48hr incubation, cleavage was not significantly 
observed. Still this data proves that cardiac glycosides extracted from Digitalis Ferrugiana 
can induce apoptosis in human liver cancer cell lines.   
In the final step of our research on cardiac glycosides extarcts from digitalis 
ferrugiana, cell cycle analysis by these molecules on cancer cell lines was tested. We 
demonstrated that, cardiac glycosides Lanatoside A, Lanatoside C and Glucogitorosid 
induces G2/M arrest in cell cycles of both Huh7 and Mahlavu liver cancer cell lines (In 
Figure 4.7 and 4.8,). Previous studies also pointed out the relation of cardiac glycosides with 
Akt pathway as well (Newman et al, 2008; Schoner and Scheiner-Bobie, 2007; Chen et al, 
2006). Thus our findings of G2/M arrest and apoptosis induction may also correlate with the 
idea that possibly Lanatoside A, Lanatoside C and Glucogitorosid induces G2/M arrest, that 
eventually causes apoptosis, through down-regulation of Akt pathway (Figure 5.1).  
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Figure 5.1: Caspase dependent apoptosis signaling cascade (Thomson 
Reuters http://www.genego.com/map_373.php) 
 
We also checked the presence of autophagy marker LC3B in cells treated with 
Lanatoside A, Lanatoside C and Glucogitorosid. Normally, LC3B is found inside the 
cytoplasm. However, it is lipidated and cleaved during autophagy. LC3B has two isoforms at 
18kDa and 16kDa. In normal cells, the 18kDa fragment is frequently found. In case of 
atuophagy, amount of 18kDa fragment decreases and 16kDa increases. In our case, in all 
samples treated with cardiac glycosides the amount of 18kDa fragment was same with 
DMSO control. Besides, there was very few 16kDa fragment (Data not shown). This data 
also confirmed that the cardiac glycosides we tested induces apoptosis, not autophagy in 
human liver cancer cell lines in the concentrations we used.  
Thus, these findings indicate that cardiac glycosides, extracted from Digitalis 
Ferrugiana, comprise high cytotoxicity against tumor cells and they induce G2/M arrest that 
leads to apoptosis induction. 
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In the second part of my thesis research, our aim was to investigate the 
characteristics of a set of molecules synthesized by Birsen Tozkoparan. These molecules 
were designed as derivatives of kinase inhibitors having similar sturctures to Imatinib and 
erlotininib (Figure5.2) . In the recent years, there has been a lot of emphasis on the 
importance of kinase inhibitors in anticancer therapeutics. The most important advantage of 
these molecules is their low side effects and relatively low toxicity against normal cells 
(Novak C, 2004). 
 
 
 
 
 
 
 
Figure 5.2: Schematic representation of Imatinib, Erlotinib, IBUTRI, IBUTRI-
nTDZ, IBUTRI-FTDZ, IBUTRI-ClTDZ (http://www.rxlist.com/tarceva-drug.htm, 
http://www.answers.com/topic/imatinib) 
 
Erlotinib 
IBUTRI 
IBUTRI-nTDZ 
IBUTRI-FTDZ 
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65 
 
Initilally, cytotoxic activities of the molecules were examined on breast (MCF7), 
colon (HCT 116)  and liver cancer (Huh7) cell lines. The group of molecules with lowest 
IC50 values was IBUTRI group. Therefore, we investigated this group of molecules in more 
detail.  As shown in Table 4.1 and 4.2 IBUTRI had the highest IC50 within the group and 
IBUTRI-nTDZ had the lowest IC50 value. This data was also confirmed by the results of the 
real-time cell growth surveillance analysis by xCelligence (Figure 4.9). The reason for 
IBUTRI having the highest IC50 compared to other group members might be the difference 
in penetration through the cell membrane. In other words, nTDZ arm as well as F or Cl 
addition might ease the penetration of the molecule inside the cell that makes them more 
cytotoxic. 
Furthermore, we confirmed the kinase inhibitory function of these molecules. It can 
be seen that IBUTRI-nTDZ has the highest kinase inhibitory effect (Figure 4.9). Erlotinib 
was used as a positive control as well as STS and Imatinib. Imatinib and STS both had high 
luciferase signal dependent on intarcellular ATP concentration since they inhibit kinase 
activity and lead to less ATP consumption in the intarcellular environment. On the other 
hand, even though erlotinib is also classified as a kinase inhibitor, we could get no luciferase 
signal. The possible reason for this might be the high cytotoxicity of the molecule thus not 
enough protein would be available to analyze.  
The last part of the project was about molecules with thiazolidine arm. Previous 
studies showed that molecules with thiazolidine have cytotoxic activity in various cancer 
cells against normal cells (Li et al, 2011; Li et al, 2007; Gududuru et al, 2005). In the first 
screen of cytotoxicity of the molecules, only one of them showed high cytotoxiciy against 
cancer cell lines (Figure 4.11 and Table 4.3). The molecule with high cytotoxicty against 
cancer cell lines was ALC67, which contains a terminal alkyne precursor. Alkynes contain 
triple bond between the two carbon atoms and they belong to the family of hydrocarbons. 
They are also called as acetylenes (Kenneth et al, 1963).  
The cytotoxic activity of ALC67 (Figure 5.3) was also verified by 
xCelligence analysis for real-time cell growth surveillance. Only the result of Cama-
1 was not satisfactory. Even though, the IC100 value was applied only 25% 
inhibition was observed. One possible reason is that cell number wasn’t confluence 
enough to distinguish between DMSO control and drug treated cells. The second 
possible reason is that cells were so confluent in SRB analysis that even a small 
amount of drug caused the cells die therefore the IC50 value calculated was too low.  
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Figure 5.3: Schematic representation of the active compound ALC67 
 
The cytotoxic activity of ALC67 was also verified by xCELLigence analysis for 
real-time cell growth surveillance. In Figure 4.12, it is obvious that ALC67 has the highest 
effect on Huh7. In addition, In MCF7, Focus, Mahlavu and T47D, cell inhibition of ALC67 
was shown to be as predicted by SRB analysis. Also it is clear that cell growth of all these 
five cell lines was effected dramatically by the interference of ALC67 when compared to 
DMSO controls.  
Finally we aimed to investigate the cell cycle arrest the compound ALC67 
caused in liver cancer cell Huh7. Our data points out SubG1/G1 arrest in cell lines 
treated with ALC67 compared to DMSO. This result supports the inverted 
microscope images in a sense that the cell death ALC67 induces is apoptosis. 
Moreover, Dr. Esra Önen had conducted a previous experiment on intrinsic apoptotic 
pathway with caspase 9 activity and the extrinsic apoptotic pathway with caspase 8  
activity in cells treated with ALC67.  She showed that its activity was dependent on 
the caspase 9 therefore intrinsic apoptotic pathway. This data also confirms our 
findings that ALC67 induces SubG1/G1 arrest which would then cause apoptosis 
induction. 
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CHAPTER 6. FUTURE PERSPECTIVES 
Our results demonstrate that all three groups of compounds that we tested can 
be considered as candidate anti-cancer therapeutic agents. Cardiac glycosides 
extracted from Digitalis Ferruginea, IBUTRI group molecules especially IBUTRI-
nTDZ and ALC67 which is a thiazolidine derivative with alkyne terminal precursor 
comprises high cytotoxic activity against cancer cell lines.  
Future experiments on further characterization and investigation of these 
molecules are listed below: 
Digitalis Ferruginea/Cardiac Glycosides Lanatoside A, Lanatoside C and 
Glucogitorosid: 
 Apoptosis can be further verified through TUNEL Assay to detect DNA 
fragmentation and Apoptotic DNA ladder kit or Annexin5 staining. 
 In order to investigate if cardiac glycosides induce mitotic chatastrophy, 
phosphorylation of Histon4Ser10 and Histon3Ser10 can be investigated using 
specific antibodies. 
 The data here reveals G2/M arrest. In order to determine if it is an M arrest or 
G2, cells will be synchronized with Nocodazole at M phase. Then Nocodazole 
will be removed and some cells will be treated with the cardiac glycosides, the 
others with DMSO. If M arrest persists in treated cells compared to DMSO 
treated cells, the conclusion will be that cardiac glycosides induce M-phase cell 
cycl arrest. 
 Then the apoptotic pathway that they induce must be clarified. In our results we 
showed the cleavage of PARP indicating the induction of caspase cascade. 
However, the caspase-related apoptosis must be verified by caspase assays such 
as Caspase 3 activity assay. 
 Furthermore, the consequences of the application of these cardiac glycosides 
must be investigated in the protein level. Previous studies showed the interaction 
of them with proteins such as but not limited to Src/EGFR, Akt, Erk, TRAIL and 
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Ras (Newman et al, 2008; Xie and Cai, 2003; Schoner and Scheiner-Bobis, 
2007; Kometiani et al, 2006) Therefore, these proteins and their active forms 
(phosphorylated) must be investigated by western blotting experiments.  
 In a study, cardiac glycosides were also related with ROS production and 
thereby apoptosis induction (Newman et al, 2008; Xie and Cai, 2003; Schoner 
and Scheiner-Bobis, 2007). Therefore, ROS assay should be performed in cells 
treated with these molecules in order to investigate the production of ROS. 
 Finally, mammalian in vivo experiments need to be performed. After generation 
of xenogarft tumors in nude-mice, they should be treated with Lanatoside A, 
Lanatoside C or Glucogitorosid. Then the progression of tumor should be 
observed. 
IBUTRI-nTDZ: 
 The cell cycle arrest can be furher investigated propidium iodide labeled FACS 
analysis. 
 Then the death pathway it induces must be determined. Since we are hypotizing 
the induction of apoptosis, western blot against PARP cleavage or Annexin V 
assay can be performed. 
 Also, to confirm the induction of apoptosis, TUNEL assay will be performed to 
investigate DNA fragmentation. 
 We have showed that the molecule inhibits kinases however which group of 
kinases are inhibited must be investigated using kinase assay kits specific for 
different groups of kinases. 
ALC67: 
 FACS analysis with BrdU incorporation will be performed to confirm and 
investigate SubG1/G1 arrest. 
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